These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 9544741)
61. Essential role for the (hepatic) LDL receptor in macrophage apolipoprotein E-induced reduction in serum cholesterol levels and atherosclerosis. Van Eck M; Van Dijk KW; Herijgers N; Hofker MH; Groot PH; Van Berkel TJ Atherosclerosis; 2001 Jan; 154(1):103-12. PubMed ID: 11137088 [TBL] [Abstract][Full Text] [Related]
62. Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E-deficient mice. Maor I; Hayek T; Coleman R; Aviram M Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2995-3005. PubMed ID: 9409286 [TBL] [Abstract][Full Text] [Related]
63. Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice. Hu L; Boesten LS; May P; Herz J; Bovenschen N; Huisman MV; Berbée JF; Havekes LM; van Vlijmen BJ; Tamsma JT Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2710-5. PubMed ID: 17038633 [TBL] [Abstract][Full Text] [Related]
64. ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice transplanted with ApoE-expressing macrophages. Boisvert WA; Black AS; Curtiss LK Arterioscler Thromb Vasc Biol; 1999 Mar; 19(3):525-30. PubMed ID: 10073953 [TBL] [Abstract][Full Text] [Related]
65. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130 [TBL] [Abstract][Full Text] [Related]
66. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Yu P; Xiong T; Tenedero CB; Lebeau P; Ni R; MacDonald ME; Gross PL; Austin RC; Trigatti BL Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):26-39. PubMed ID: 29162602 [TBL] [Abstract][Full Text] [Related]
67. Foam cells from aorta and spleen overexpress apolipoprotein E in the absence of hypercholesterolemia. Crespo P; Ros MA; Ordovás JM; Rodriguez JC; Ortiz JM; León J Biochem Biophys Res Commun; 1992 Mar; 183(2):514-23. PubMed ID: 1550559 [TBL] [Abstract][Full Text] [Related]
68. Accelerated atherosclerosis and calcification in vein grafts: a study in APOE*3 Leiden transgenic mice. Lardenoye JH; de Vries MR; Löwik CW; Xu Q; Dhore CR; Cleutjens JP; van Hinsbergh VW; van Bockel JH; Quax PH Circ Res; 2002 Oct; 91(7):577-84. PubMed ID: 12364385 [TBL] [Abstract][Full Text] [Related]
69. Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Hayek T; Kaplan M; Raz A; Keidar S; Coleman R; Aviram M Atherosclerosis; 2002 Mar; 161(1):65-74. PubMed ID: 11882318 [TBL] [Abstract][Full Text] [Related]
70. Stimulatory effects of cardiotrophin 1 on atherosclerosis. Konii H; Sato K; Kikuchi S; Okiyama H; Watanabe R; Hasegawa A; Yamamoto K; Itoh F; Hirano T; Watanabe T Hypertension; 2013 Nov; 62(5):942-50. PubMed ID: 24041953 [TBL] [Abstract][Full Text] [Related]
71. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. Tangirala RK; Praticó D; FitzGerald GA; Chun S; Tsukamoto K; Maugeais C; Usher DC; Puré E; Rader DJ J Biol Chem; 2001 Jan; 276(1):261-6. PubMed ID: 11024044 [TBL] [Abstract][Full Text] [Related]
72. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Babaev VR; Gleaves LA; Carter KJ; Suzuki H; Kodama T; Fazio S; Linton MF Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2593-9. PubMed ID: 11116058 [TBL] [Abstract][Full Text] [Related]
73. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. Marleau S; Harb D; Bujold K; Avallone R; Iken K; Wang Y; Demers A; Sirois MG; Febbraio M; Silverstein RL; Tremblay A; Ong H FASEB J; 2005 Nov; 19(13):1869-71. PubMed ID: 16123174 [TBL] [Abstract][Full Text] [Related]
74. Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation. Takahashi S J Atheroscler Thromb; 2017 Jun; 24(6):552-559. PubMed ID: 28428482 [TBL] [Abstract][Full Text] [Related]
75. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883 [TBL] [Abstract][Full Text] [Related]
76. The APO(*)E3-Leiden mouse as an animal model for basal laminar deposit. Kliffen M; Lutgens E; Daemen MJ; de Muinck ED; Mooy CM; de Jong PT Br J Ophthalmol; 2000 Dec; 84(12):1415-9. PubMed ID: 11090485 [TBL] [Abstract][Full Text] [Related]